Carmot Therapeutics Stock
HealthTechLooking to sell Carmot Therapeutics stock or options?
Carmot Therapeutics Inc, a clinical-stage biotech firm, is committed to creating transformative treatments for individuals suffering from metabolic disorders such as obesity and diabetes. The company has three clinical-stage product candidates in its pipeline: CT-388, a once-weekly injectable dual GLP-1/GIP receptor agonist for combating obesity and type 2 diabetes (T2D); CT-996, a once-daily oral small molecule GLP-1 receptor agonist also aimed at treating obesity and T2D; and CT-868, a once-daily injectable dual GLP-
5AM Ventures, Ponoi Capital, TCG Crossover Management, Michael J. Fox Foundation, Amgen, RA Capital Management, Millennium Management, National Science Foundation, Willett Advisors, Venrock, National Cancer Institute, Franklin Templeton, Deep Track Capital, Janus Henderson Investors, Horizons Ventures, QB3, The Column Group, Qualifying Therapeutic Discovery Project, Jerome Dahan, Frazier Lifesciences Acquisition.